山西振东制药股份有限公司 2024年年度股东大会决议公告 证券代码：300158 证券简称：振东制药 公告编号：2025-030 3、召开地点：北京市海淀区创业路 18 号北京振东科技大厦 4 层 会议室 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情 形。 一、会议召开和出席情况 1、召开时间：2025 年 5 月 14 日（星期三）上午 09:00 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 14 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 14 日 9:15-15:00。 6、主持人：董事长李昆先生 4、召开方式：现场投票和网络投票 7、参加本次股东大会的股东及股东代表共计 353 人，代表有表 决权的公司股份数为 359,834,885 股，占公司有表决权股份总数的 36.2589%（指 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-031 山西振东制药股份有限公司 关于参加山西辖区上市公司 2025 年投资者网上 集体接待日暨年报业绩说明会活动的公告 2025 年 5 月 14 日 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山西振东制药股份有限公司 （以下简称"公司"）将参加由中国证券监督管理委员会山西监管局、 山西省上市公司协会与深圳市全景网络有限公司联合举办的"山西辖 区上市公司 2025 年投资者集体接待日暨年报业绩说明会"活动，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景 路演 APP，参与本次互动交流，活动时间为 2025 年 5 月 20 日（周二） 15:00-17:00。出席本次投资者网上集体接待日活动的公司人员有：公 司董事长李昆先生、独立董事靳黎娜女士、董事会秘书王哲宇先生、 财务总监詹建勇先生，届时将在线就公司 2024 年度业绩、公司治理、 ...

Group 1 - The company announced a change in the location of the 2024 Annual General Meeting (AGM) from Shanxi to Beijing to facilitate shareholder attendance [2][3] - As of March 31, 2025, the company had 48,600 ordinary shareholders, with the record date for the AGM being May 8, 2025 [3] - The sudden change in the meeting location may catch shareholders off guard, especially those who had already planned their travel arrangements [4] Group 2 - The company reported a revenue of 2.971 billion yuan for the previous year, a year-on-year decrease of 18.06%, and a net profit attributable to shareholders of -1.329 billion yuan, a decrease of 2920.55% [4] - In the first quarter of this year, the company achieved a revenue of 755 million yuan, down 3.53% year-on-year, with a net profit of 1.1572 million yuan, a decline of 94.99% [4] - The AGM will address critical matters such as the company's 2024 profit distribution plan and the reappointment of the auditing firm for the 2025 financial report, which are vital for the company's operational stability and shareholder interests [4]

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-029 山西振东制药股份有限公司 关于变更 2024 年年度股东大会现场会议地点的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 特别提示：山西振东制药股份有限公司（以下简称"公司"）2024 年年度股东大会现场会议地点变更为：北京市海淀区创业路 18 号北 京振东科技大厦 4 层会议室。敬请投资者注意。 公司拟于 2025 年 5 月 14 日（星期三）召开公司 2024 年年度股 东大会，具体内容详见 2025 年 4 月 21 日披露于巨潮资讯网 （www.cninfo.com.cn）的《关于召开 2024 年年度股东大会的通知》 （公告编号：2025-025）及 2025 年 5 月 7 日披露于巨潮资讯网 （www.cninfo.com.cn）的《关于召开 2024 年年度股东大会的提示性 公告》（公告编号：2025-028）。 为便于股东参会，公司决定将 2024 年年度股东大会现场会议地 点变更为：北京市海淀区创业路18号北京振东科技大厦4层会议 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-027 山西振东制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"） 分别于 2024 年 10 月 22 日、11 月 12 日召开公司第六届董事会第二 次会议、2024 年第二次临时股东大会，审议通过了《关于回购公司 股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分股份，回购的股份将全部用于注销并减少公司注册资本。本 次用于回购股份的资金总额上限为人民币 10,000 万元，回购下限为 人民币 5,000 万元，回购价格不超过人民币 6.00 元/股（含本数）， 回购股份的实施期限为自公司股东大会审议通过本次回购股份方案 之日起不超过 12 个月。具体内容详见公司于 2024 年 10 月 24 日、2024 年 11 月 12 日刊登在巨潮资讯网（www.cninfo.com.cn）的相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等相关规定， ...

证券代码：300158 证券简称：振东制药 公告编号：2025-028 山西振东制药股份有限公司 关于召开 2024 年年度股东大会的提示性公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 山西振东制药股份有限公司（以下简称"公司"）第六届董事会第 三次会议审议通过了《关于召开 2024 年年度股东大会的议案》，决 定于 2025 年 5 月 14 日（星期三）召开公司 2024 年年度股东大会， 并已于 2025 年 4 月 21 日在巨潮资讯网（www.cninfo.com.cn）披露了 《关于召开 2024 年年度股东大会的通知》（公告编号：2025-025）。 为进一步保护投资者的合法权益，方便各位股东行使股东大会表 决权，现将会议有关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、会议召集人：山西振东制药股份有限公司（以下简称"公司"） 董事会 3、会议召开的合法、合规：公司第六届董事会第三次会议决议 通过《关于召开 2024 年年度股东大会的议案》，本次股东大会的召 集 ...

Core Viewpoint - 2024 is a significant downturn year for Zhending Pharmaceutical, marked by substantial financial losses and operational challenges, revealing both immediate and long-term vulnerabilities in the company's business model [2][3]. Financial Performance - The company reported a total revenue of 2.971 billion yuan in 2024, a year-on-year decline of 18.06% - The net profit attributable to shareholders was a loss of 1.329 billion yuan, representing a staggering year-on-year drop of 2920.55% - The non-recurring net profit was -686 million yuan, down 491.35% year-on-year [2][5]. Non-Operating Losses - Major non-operating losses stemmed from an arbitration dispute with former subsidiary Beijing Landi Pharmaceutical, which resulted in a 1.4 billion yuan penalty for producing substandard drugs - The arbitration claim amounted to 1.467 billion yuan, with a settlement of 500 million yuan directly impacting the company's financials, accounting for 46.36% of total profit for the period [3][4]. Core Business Weakness - The pharmaceutical production and sales revenue fell to 2.313 billion yuan, down 20.50% year-on-year, while the medicinal plant cultivation revenue decreased to 634 million yuan, a decline of 8.99% - The simultaneous contraction in core business areas indicates a persistent weakening of market competitiveness [5][6]. Product Competition - The company's key products, including Fufang Kucan Injection and Dafeixin Minoxidil Lotion, face increasing competition in the market - Dafeixin's market share rose to 47.3% in 2024, but it does not hold the patent for Minoxidil, exposing it to competitive risks from other players like Sanofi's Mandi, which commands a 72.6% market share in the Minoxidil sector [6][7]. Innovation and R&D Challenges - The company has faced significant setbacks in innovation, with 27 drugs entering national or provincial procurement, but 8 of these had zero actual procurement volumes - The termination of several key R&D projects indicates a lack of new product development, which is critical for future growth [8][9]. International Expansion and Cost Management - Despite claims of pursuing international registration for Fufang Kucan Injection and other initiatives, R&D expenses were only 351 million yuan, about 11.82% of revenue, with no substantial progress reported - The gross margin for medicinal plant cultivation was only 12.7%, significantly lower than industry leader Tongrentang, which exceeds 25% [10].

Core Viewpoint - In 2024, Zhendong Pharmaceutical faced multiple operational challenges leading to a significant deterioration in its financial condition, with a reported revenue decline of 18.06% and a net loss of 1.33 billion yuan [1][3]. Financial Performance - The company's total revenue for 2024 was 2.971 billion yuan, down from the previous year [1][3]. - The net profit attributable to shareholders was a loss of 1.329 billion yuan, a substantial increase from a loss of 43.98 million yuan in 2023 [1][3]. - The non-recurring net profit also showed a loss of 686 million yuan, significantly higher than the previous year's loss of 116 million yuan [1][3]. Business Segments - Zhendong Pharmaceutical's two main business segments, pharmaceutical production and sales, and medicinal herb planting, both experienced declines [1][3]. - Revenue from pharmaceutical production and sales was 2.313 billion yuan, a decrease of 20.50% year-on-year [1][3]. - Revenue from medicinal herb planting and sales was 634 million yuan, down 8.99% year-on-year [1][3]. Regulatory Issues - In October 2023, a subsidiary, Landi Pharmaceutical, faced administrative penalties for 32 batches of calcium carbonate D3 granules failing inspections, resulting in a fine of 134 million yuan and a confiscation of illegal gains of 6.18 million yuan [2][7]. - In September 2024, Landi Pharmaceutical initiated arbitration against Zhendong Pharmaceutical for 1.467 billion yuan, leading to a final compensation payment of 500 million yuan by Zhendong [2][6][7]. Shareholder Actions - Since its listing, Zhendong Pharmaceutical has seen significant shareholder sell-offs, with a total of 176.2 million shares sold, amounting to 1.359 billion yuan [2][8]. - The controlling shareholder, Li Anping, has personally cashed out 706 million yuan through share reductions [2][8].

Core Viewpoint - The internationalization of traditional Chinese medicine (TCM) faces significant challenges, including the lack of unified international standards, difficulties in dialogue between Chinese and Western medicine, and insufficient clinical efficacy evidence. The company emphasizes quality and research as primary strategies for international expansion, followed by market considerations [1][3]. Group 1: Quality Assurance - The quality of medicinal materials is crucial as it directly affects the efficacy of drugs. Various factors influence the quality, including the geographical origin of the materials, harvesting seasons, processing methods, and storage techniques [3]. - The company has been exploring traceability in medicinal materials to ensure product quality over the years [3]. Group 2: Research and Evidence - The company aims to strengthen the acceptance of TCM among overseas doctors by building a robust evidence chain through scientific research. This is essential for enhancing public recognition of TCM products [3]. - There is a need for collaborative research efforts to provide sufficient evidence for regulatory acceptance, which is vital for advancing internationalization [3]. Group 3: Market Expansion - The company is also exploring the export of TCM functional foods, aiming to expand beyond the Chinese community into larger markets, contingent on maintaining quality and research foundations [3]. - The internationalization process for TCM companies is lengthy and challenging, requiring multiple cycles of "going out, bringing in, and going out again" [4].